• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Amneal Pharmaceuticals Inc (NY: AMRX )

    N/A UNCHANGED
    Last Price Updated: 7:00 PM EST, Dec 26, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open -
    Bid (Size) 5.710 (1)
    Ask (Size) 6.000 (1)
    Prev. Close 5.870
    Today's Range N/A - N/A
    52wk Range 3.960 - 5.800
    Shares Outstanding 1,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal to Participate at Upcoming Investor Conference
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    More News

    Read More
    Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
    Via InvestorPlace
    Topics Intellectual Property
    Exposures Intellectual Property
    Assessing Amneal Pharmaceuticals: Insights From 4 Financial Analysts
    Via Benzinga
    Generic Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit Settlement
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Amneal Pharmaceuticals: Q4 Earnings Insights
    Via Benzinga
    Earnings Outlook For Amneal Pharmaceuticals
    Via Benzinga
    AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Amneal Reports First Quarter 2024 Financial Results
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal to Report First Quarter 2024 Results on May 3, 2024
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Why Is Generic Drug-Focused Amneal Pharmaceuticals Stock Trading Lower Friday?
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Earnings Scheduled For March 1, 2024
    Via Benzinga
    Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    6 reasons to buy Teva Pharmaceuticals stock sooner than later
    Via MarketBeat
    Topics Lawsuit
    Exposures Financial Legal
    Amneal to Participate at Upcoming Investor Conference
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.